Cipher Pharmaceuticals Inc.
TSX:CPH Stock Report
Cipher Pharmaceuticals Past Earnings Performance Cipher Pharmaceuticals has been growing earnings at an average annual rate of 43%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been declining at an average rate of 0.1% per year. Cipher Pharmaceuticals's return on equity is 16%, and it has net margins of 59.9%.
Key information
43.0%
Earnings growth rate
Pharmaceuticals Industry Growth 23.1% Revenue growth rate -0.1% Return on equity 16.0% Net Margin 59.9% Last Earnings Update 30 Sep 2024
Recent past performance updates
Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think Nov 14
Third quarter 2024 earnings: EPS misses analyst expectations Nov 09
Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 04
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 09
Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023) May 10
Show all updates
Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think Nov 14
Investor sentiment deteriorates as stock falls 15% Nov 14
With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For Nov 12
Price target increased by 10% to CA$18.59 Nov 10
Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now Nov 09
Third quarter 2024 earnings: EPS misses analyst expectations Nov 09
Price target increased by 7.4% to CA$17.37 Nov 08
Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 04
Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer Oct 08
Investor sentiment improves as stock rises 16% Oct 03
Investor sentiment deteriorates as stock falls 17% Sep 16
Investor sentiment improves as stock rises 19% Aug 19
Consensus EPS estimates increase by 10% Aug 15
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 09 Cipher Pharmaceuticals Inc. Announces CFO Changes
Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
Consensus revenue estimates increase by 37% Jul 30
Investor sentiment improves as stock rises 16% Jul 30
First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023) May 10
Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024 Apr 09
There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise Mar 23
Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH) Mar 22
Investor sentiment improves as stock rises 27% Mar 21
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 15
Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024 Mar 09
Investor sentiment improves as stock rises 16% Feb 05
Investor sentiment improves as stock rises 15% Jan 04
Consensus EPS estimates increase by 53% Nov 16
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 12
Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 28
Investor sentiment improves as stock rises 15% Sep 11 Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares. Sep 06
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 11
Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
Less than half of directors are independent Jun 03
Consensus EPS estimates increase by 17% Jun 02
Consensus revenue estimates decrease by 12% May 18
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 12
Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Interim CEO & Chairman of the Board exercised options to buy CA$411k worth of stock. Apr 11
Interim CEO & Chairman of the Board exercised options to buy CA$462k worth of stock. Apr 02
Full year 2022 earnings: EPS exceeds analyst expectations Mar 17
Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023 Feb 14
Independent Director recently sold CA$61k worth of stock Dec 15
Price target increased to CA$4.13 Nov 16
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 12
Cipher Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 27
Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021) Aug 12
Cipher Pharmaceuticals Inc. Announces Appointment of Bryan Jacobs as Chief Financial Officer Aug 12
Cipher Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 06
John Mull Decides Not to Stand for Re-Election as Director of Cipher Pharmaceuticals Inc Jun 23
Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock May 14
First quarter 2022 earnings: EPS exceeds analyst expectations May 13 Cipher Pharmaceuticals Inc. to Report Q1, 2022 Results on May 12, 2022 May 10
Price target increased to CA$3.30 Apr 27
Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 22, 2022 Apr 19
Full year 2021 earnings: EPS exceeds analyst expectations Mar 19
Investor sentiment improved over the past week Feb 08
Investor sentiment improved over the past week Dec 25
Investor sentiment deteriorated over the past week Nov 30
Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020) Nov 12
Investor sentiment improved over the past week Sep 08
Consensus EPS estimates increase to US$0.31 Aug 19
Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020) Aug 14
Price target increased to CA$1.82 Aug 14
Investor sentiment improved over the past week Aug 13
Investor sentiment improved over the past week Jun 12
Consensus revenue estimates increase to US$21.5m May 20
Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH) May 18
First quarter 2021 earnings released: EPS US$0.05 (vs US$0.092 in 1Q 2020) May 16
Consensus EPS estimates fall to US$0.17 May 01
Investor sentiment improved over the past week Mar 25
Price target increased to CA$1.69 Mar 23
Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next Mar 20
Cipher Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 18, 2021 Mar 11
Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12% Jan 26
Price target raised to CA$1.65 Jan 20
Cipher Pharmaceuticals Receives Arbitration Award on Trulance Jan 16
Investor sentiment improved over the past week Jan 08
New 90-day high: CA$1.15 Jan 08
Third quarter 2020 earnings released: EPS US$0.06 Nov 15
Revenue and earnings beat expectations Nov 15
New 90-day low: CA$0.93 Nov 11
Cipher Pharmaceuticals Inc. to Report Q3, 2020 Results on Nov 12, 2020 Nov 05
New 90-day low: CA$1.02 Oct 20
Cipher Pharmaceuticals Inc. Approves the Appointment of Cathy Steiner as Director Oct 10
New 90-day low: CA$1.09 Sep 24
New 90-day low - CA$1.13 Aug 28
Earnings released Aug 14
Revenue & Expenses Breakdown
How Cipher Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History TSX:CPH Revenue, expenses and earnings (USD Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Sep 24 26 16 9 0 30 Jun 24 22 23 6 0 31 Mar 24 22 23 6 0 31 Dec 23 21 20 5 0 30 Sep 23 21 32 5 0 30 Jun 23 20 28 5 0 31 Mar 23 20 27 5 0 31 Dec 22 21 27 5 0 30 Sep 22 22 10 5 0 30 Jun 22 21 8 5 0 31 Mar 22 22 9 5 0 31 Dec 21 22 8 5 0 30 Sep 21 22 5 6 0 30 Jun 21 23 6 6 0 31 Mar 21 21 3 6 0 31 Dec 20 22 4 6 0 30 Sep 20 21 7 6 0 30 Jun 20 22 3 5 0 31 Mar 20 23 4 6 0 31 Dec 19 22 3 8 0 30 Sep 19 23 -1 11 0 30 Jun 19 22 2 13 0 31 Mar 19 23 3 14 1 31 Dec 18 23 1 14 1 30 Sep 18 28 6 13 1 30 Jun 18 34 9 13 0 31 Mar 18 37 11 13 0 31 Dec 17 40 11 13 0 30 Sep 17 34 7 13 0 30 Jun 17 32 5 13 0 31 Mar 17 31 1 14 1 31 Dec 16 30 4 16 1 30 Sep 16 33 6 23 1 30 Jun 16 34 2 28 0 31 Mar 16 34 1 29 0 31 Dec 15 34 2 29 1 30 Sep 15 32 3 21 1 30 Jun 15 30 13 14 1 31 Mar 15 30 18 10 1 31 Dec 14 29 19 9 1 30 Sep 14 33 31 7 1 30 Jun 14 32 27 7 1 31 Mar 14 29 25 7 0 31 Dec 13 25 24 6 0
Quality Earnings: CPH has a high level of non-cash earnings .
Growing Profit Margin: CPH's current net profit margins (59.9%) are lower than last year .
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CPH has become profitable over the past 5 years, growing earnings by 43% per year.
Accelerating Growth: CPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CPH had negative earnings growth (-51.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-51.1%).
Return on Equity
High ROE: CPH's Return on Equity (16%) is considered low .
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
